JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences (NASDAQ:GILD) had its price target lifted by JPMorgan Chase & Co. from $170.00 to $190.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price indicates a potential upside of 11.32% from the company’s current price.

Other equities research analysts also recently issued research reports about the stock. HSBC boosted their target price on shares of Gilead Sciences from $155.00 to $175.00 and gave the stock a “buy” rating in a research report on Thursday, September 10th. Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $146.00 to $127.00 in a research report on Tuesday, July 21st. UBS Group restated a “buy” rating and issued a $195.00 price objective on shares of Gilead Sciences in a research report on Friday. Jefferies Financial Group reaffirmed a “buy” rating and set a $185.00 price target on shares of Gilead Sciences in a research report on Friday, October 23rd. Finally, Truist Financial upped their price objective on Gilead Sciences from $158.00 to $181.00 and gave the company a “buy” rating in a research note on Friday. Twenty-three research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences has an average rating of “Moderate Buy” and an average price target of $169.19.

Gilead Sciences Price Performance

Gilead Sciences stock traded up $5.07 during mid-day trading on Friday, hitting $170.68. The stock had a trading volume of 11,425,175 shares, compared to its average volume of 6,817,515. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. Gilead Sciences has a one year low of $114.02 and a one year high of $175.65. The firm’s 50 day moving average is $150.33 and its 200 day moving average is $139.55. The firm has a market capitalization of $211.63 billion, a P/E ratio of -63.93 and a beta of 0.31.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Friday, October 30th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative net margin of 10.64% and a negative return on equity of 2.11%. The business had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. During the same period in the previous year, the company posted $2.47 earnings per share. The firm’s revenue was up 6.8% on a year-over-year basis. On average, sell-side analysts forecast that Gilead Sciences will post -0.48 earnings per share for the current fiscal year.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the sale, the insider directly owned 113,684 shares in the company, valued at approximately $17,759,714.48. The trade was a 2.57% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the sale, the director directly owned 10,066 shares of the company’s stock, valued at $1,459,771.32. The trade was a 33.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 111,000 shares of company stock valued at $15,877,860. Corporate insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Several institutional investors and hedge funds have recently modified their holdings of the business. PFS Partners LLC grew its stake in Gilead Sciences by 101.1% in the third quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 96 shares during the period. Persistent Asset Partners Ltd bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at $25,000. Laurel Wealth Advisors LLC purchased a new stake in Gilead Sciences during the third quarter valued at approximately $29,000. Kimelman & Baird LLC purchased a new position in Gilead Sciences during the 2nd quarter worth $25,000. Finally, Toth Financial Advisory Corp lifted its holdings in Gilead Sciences by 85.5% in the third quarter. Toth Financial Advisory Corp now owns 217 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 100 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
• Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
• Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
• Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
• Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
• Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.